Literature DB >> 24557664

To restrict indication for stenting of the inferior vena cava and liver transplantation in patients with Budd-Chiari syndrome.

Zhonggao Wang1.   

Abstract

The Budd-Chiari syndrome (BCS) used to be a very rare disorder and lacked a means of relieving. However, various shuntings and radical procedures have emerged in the last three decades with quite encouraging outcomes. Recent minimally invasive therapies, such as stenting of the inferior vena cava (IVC), are simple and easy to handle. However, it has been realized that the IVC stent may compromise the hepatic veins and cause catastrophic consequences, thus the indication for IVC stenting should be reevaluated and especially not to be overused. Instead, it should be applied by percutaneous transangiography (PTA) only, which may be repeated when necessary. The BCS in China predominantly belongs to the IVC type rather than the intrahepatic type in Western; the outcome from its conventional therapy, at least for the moment, is better than that of liver transplantation. It is thus suggested that, before liver transplantation is decided, the conventional means for managing BCS be considered. The final suggestion is to restrict the indication both for stenting of the IVC and liver transplantation. In this paper, ten examples are given with figures.

Entities:  

Year:  2007        PMID: 24557664     DOI: 10.1007/s11684-007-0025-3

Source DB:  PubMed          Journal:  Front Med China        ISSN: 1673-7342


  2 in total

1.  Evolution of management for Budd-Chiari syndrome: a team's view from 2564 patients.

Authors:  Zhong Gao Wang; Feng Ji Zhang; Meng Qing Yi; Li Xiao Qiang
Journal:  ANZ J Surg       Date:  2005 Jan-Feb       Impact factor: 1.872

2.  Recognition and management of Budd-Chiari syndrome: report of one hundred cases.

Authors:  Z G Wang; Y Zhu; S H Wang; L P Pu; Y H Du; H Zhang; C Yuan; Z Chen; M L Wei; L Q Pu
Journal:  J Vasc Surg       Date:  1989-08       Impact factor: 4.268

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.